Pages that link to "Q38889135"

The following pages link to Hepcidin regulation in prostate and its disruption in prostate cancer. (Q38889135):

Displaying 45 items.

• Pharmacological Targeting of the Hepcidin/Ferroportin Axis (Q26738350) (← links)
• Targeting iron metabolism in drug discovery and delivery (Q33757232) (← links)
• Extratumoral Heme Oxygenase-1 (HO-1) Expressing Macrophages Likely Promote Primary and Metastatic Prostate Tumor Growth (Q36046653) (← links)
• Local iron homeostasis in the breast ductal carcinoma microenvironment (Q36654277) (← links)
• Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease (Q36665139) (← links)
• SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation (Q36800327) (← links)
• Modulation of hepcidin to treat iron deregulation: potential clinical applications (Q36847852) (← links)
• Iron and cancer: recent insights (Q36909297) (← links)
• Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts (Q37638804) (← links)
• DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms (Q37686041) (← links)
• Malignancies and thalassemia: a review of the literature (Q38750541) (← links)
• SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways. (Q38759773) (← links)
• Hepcidin: Homeostasis and Diseases Related to Iron Metabolism (Q39313303) (← links)
• Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancer (Q41050245) (← links)
• Iron addiction: a novel therapeutic target in ovarian cancer (Q41211121) (← links)
• Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer (Q41709616) (← links)
• Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells (Q47097927) (← links)
• Dysregulated lncRNA-UCA1 contributes to the progression of gastric cancer through regulation of the PI3K-Akt-mTOR signaling pathway (Q47139829) (← links)
• Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. (Q47161414) (← links)
• Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth (Q47164877) (← links)
• Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer. (Q47615199) (← links)
• Hepcidin and DNA promoter methylation in hepatocellular carcinoma. (Q48128368) (← links)
• Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology (Q48623654) (← links)
• Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. (Q49389245) (← links)
• Increased expression of hepcidin and associated upregulation of JAK/STAT3 signaling in human gastric cancer (Q49863923) (← links)
• Hepcidin, an emerging and important player in brain iron homeostasis (Q49885816) (← links)
• Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. (Q52562759) (← links)
• DNA methylation of hepatic iron sensing genes and the regulation of hepcidin expression. (Q54943445) (← links)
• Role of hepcidin and iron metabolism in the onset of prostate cancer. (Q55144988) (← links)
• Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. (Q55408493) (← links)
• Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer. (Q55497286) (← links)
• The Hepcidin/Ferroportin axis modulates proliferation of pulmonary artery smooth muscle cells (Q58699655) (← links)
• E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin (Q58700293) (← links)
• Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies (Q59807273) (← links)
• Iron in the Tumor Microenvironment-Connecting the Dots (Q59808741) (← links)
• Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma (Q61447928) (← links)
• Iron as a Central Player and Promising Target in Cancer Progression (Q61796322) (← links)
• Differentially Expressed Genes and Molecular Pathways in an Autochthonous Mouse Prostate Cancer Model (Q64118105) (← links)
• Iron and leukemia: new insights for future treatments (Q90098447) (← links)
• HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway (Q91740498) (← links)
• FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels (Q92615413) (← links)
• Extrahepatic hepcidin production: The intriguing outcomes of recent years (Q92685570) (← links)
• Hepcidin Therapeutics (Q93373791) (← links)
• SOSTDC1 promotes invasion and liver metastasis in colorectal cancer via interaction with ALCAM/CD166 (Q98499774) (← links)
• Iron deficiency in children at the time of initial neuroblastoma diagnosis (Q98772439) (← links)